WESTON, Fla., June 1, 2011 (GLOBE NEWSWIRE) -- Stemlogix, a leader in providing veterinarians with innovative regenerative medicine solutions, introduces its proprietary equine VetLipo™ procedure. The equine VetLipo™ procedure is an innovative technique to remove stem cell-rich adipose (fat) tissue from horses in a minimally invasive, scar-free method. VetLipo™ was pioneered by a leading physician and Stemlogix Co-Founder, Dr. Sharon McQuillan. Dr. McQuillan has trained hundreds of human surgeons from around the world on minimally invasive lipoaspirate procedures and is now making similar cutting-edge techniques available to equine veterinarians. The technique involves using a proprietary cannula and syringe which creates enough of a vacuum (without needing a vacuum pump) to remove, or aspirate, fat tissue from the base of the tail in horses. The incision needed is only about a millimeter and does not even require stitches. VetLipo™ is also designed to remove fat in a way that protects the millions of regenerative stem cells within the tissue. Traditional techniques of removing fat tissue involve a more invasive surgical approach which requires stitches and tends to leave a noticeable scar on the horse.
The fat tissue that is extracted by the innovative VetLipo™ procedure can then be processed on-site with Stemlogix portable equipment and kits to isolate millions of regenerative stem cells. The stem cells are directly injected into a diseased or damaged area in order to accelerate healing and repair in horses suffering from tendon injuries, ligament injuries and/or arthritis.
"We are excited to be able to introduce the VetLipo™ technique which lessens the impact and the scarring on equine patients compared to traditional surgical approaches of removing fat tissue," said Dr. McQuillan. "We called upon our many years of experience in human lipoaspiration to develop this procedure for equine regenerative medicine and we took great care to develop a process that maximized the number of stem cells that can be harvested."
Stemlogix has a history of introducing innovative regenerative medicine solutions for veterinarians. Last year, Stemlogix launched its premier in-clinic stem cell therapy program which allows veterinarians to provide their patients highly viable stem cell therapy in an affordable, same-day procedure. The Stemlogix stem cell process can be performed in about an hour within a sterile environment with the use of the company's portable clean room hood. This approach is revolutionary because veterinarians are now able to produce stem cell therapy in a clinic or on-site where a patient is located as opposed to shipping tissue to a remote laboratory, a process that takes 48 hours. Stem cells have a limited lifespan outside of the body and by producing the stem cells on-site the viability of the cells is maintained. The cost of the Stemlogix therapy is far lower than traditional methods so it can be offered to more clients and it only requires one office visit for both fat tissue extraction and stem cell delivery.
About Stemlogix, LLC
Stemlogix is an innovative veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the best possible stem cell therapy to dogs, cats and horses at the point-of-care. Stemlogix provides veterinarians with the ability to isolate regenerative stem cells from a patient's own adipose (fat) tissue directly on-site within their own clinic or where a patient is located. Regenerative stem cells isolated from adipose tissue have been shown in studies to be effective in treating animals suffering from osteoarthritis, joint diseases, tendon injuries and heart disorders, among other conditions. Stemlogix has a highly experienced management team with over 20 years combined experience in developing stem cell therapeutics for both human and animal use. The Stemlogix team has experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development and enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical and preclinical studies with multiple cell types for multiple indications, and more.
For more information about veterinary regenerative medicine please visit .
CONTACT: Jason Griffeth Chief Operating Officer Stemlogix, LLC Phone: (954) 260-7118 Email: jason@stemlogix.com